Abstract
POWER 1 and 2: combined final 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patients
Highlights
Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1758-2652-11-S1-info.pdf
POWER 1 and 2 (TMC114-C213 and C202) are randomised, controlled, Phase IIb trials designed to evaluate the long-term efficacy and safety of darunavir co-administered with low-dose ritonavir (DRV/r) in comparison with control protease inhibitor (CPIs) in treatment-experienced HIV patients
The primary efficacy end-point was the proportion of patients with ≥1 log10 HIV-RNA reduction at week 144 from baseline in the intent-to-treat (ITT) population
Summary
POWER 1 and 2: combined final 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patients. Address: 1Hôpital Pitié-Salpêtrière, Paris, France, 2Southwest Infectious Disease Associates, Dallas, USA, 3Instituto de Pesquisa Clinica Evandro Chagas-FIOCRUZ, Rio de Janeiro, Brazil, 4Clinic of Infectious Diseases, Milan, Italy, 5Chelsea and Westminster Hospital, London, UK and 6Tibotec BVBA, Mechelen, Belgium. Published: 10 November 2008 Journal of the International AIDS Society 2008, 11(Suppl 1):P21 doi:10.1186/1758-2652-11-S1-P21. Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1758-2652-11-S1-info.pdf
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
